This clinical trial is focused on patients who have undergone a Roux-en-Y gastric bypass, a type of weight-loss surgery. The study is examining how this surgery affects the absorption of a medication called Apixaban, which is a blood thinner used to prevent blood clots. The trial will also involve other medications, including Beriplex, Norit, and Ondexxya, which are used as reversal agents to counteract the effects of blood thinners.
The purpose of the study is to understand how the body processes Apixaban before and after the surgery. Participants will receive the medication and have their blood levels checked at different times: before the surgery, shortly after, and a few months later. This will help researchers see how the surgery impacts the medication’s effectiveness. The study will also monitor participants’ weight and body mass index (BMI) changes, as well as any major bleeding events or occurrences of blood clots, such as pulmonary embolism or deep vein thrombosis.
The study is expected to run until 2026, with recruitment starting in 2025. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on how Roux-en-Y gastric bypass surgery affects the absorption and effectiveness of Apixaban and other related medications.
The Netherlands 
